†Please see additional dosing information.
‡Inadequate response to a prior medication was defined as: (1) no clinically meaningful improvement after at least 3 months (2) patient could not tolerate the drug (3) drug was contraindicated for patient or (4) drug was not suitable for the patients.3
§Two human factor studies assessed evaluators’ ability to complete critical tasks in order to demonstrate use of the AJOVY Autoinjector in simulated-use sessions. When asked, “Was the autoinjector easy to use?”, 97% in study 1 (N=30) and 98% in study 2 (N=47) answered “Yes.”4
CGRP: calcitonin gene-related peptide; SC: subcutaneous.
References: 1. AJOVY® (fremanezumab-vfrm) injection Current Prescribing Information. North Wales, PA: Teva Pharmaceuticals USA, Inc. 2. Blumenfeld AM, Stevanovic DM, Ortega M, et al. Headache. 2020;60(10):2431-2443. 3. Ferrari MD, Diener HC, Ning X, et al. Fremanezumab versus placebo for migraine prevention in patients with documented failure to up to four migraine preventive medication classes (FOCUS): a randomised, double-blind, placebo-controlled, phase 3b trial [published online August 16, 2019].
Lancet. doi:10.1016/S0140-6736(19)31946-4 4. Data on file. Parsippany, NJ: Teva Pharmaceuticals USA, Inc.
